Advertisement

Topics

Companies Related to "Multiple Myeloma Therapeutics Major Developed Markets 2021 Growth" [Most Relevant Company Matches] RSS

22:48 EST 16th February 2019 | BioPortfolio

Here are the most relevant search results for "Multiple Myeloma Therapeutics Major Developed Markets 2021 Growth" found in our extensive corporate database of over 50,000 company records.

Showing "Multiple Myeloma Therapeutics Major Developed Markets 2021 Growth" Companies 1–25 of 9,200+

Extremely Relevant

Multiple Myeloma Research Foundation (MMRF)

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2010, more than 20,000 adults in the United States will be diagnosed with multiple myeloma and nearly 11,000 people are predicted to die from the disease.


The Multiple Myeloma Research Consortium (MMRC)

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2011, more than 20,000 adults in the United States will be diagnosed with multiple myeloma and nearly 11,000 people are predicted to die from the disease.

The Multiple Myeloma Research Foundation

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 34 percent, one of the lowest of all cancers. In 2009, approximately 20,000 adults in the United States were diagnosed with multiple myeloma and approximately 11,000 people died from the disease.


Multiple Myeloma Research Foundation

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to ...

Kesios Therapeutics

Kesios is developing novel therapeutics for the treatment of multiple myeloma and other cancers. KES-0001, the company’s lead drug candidate, is about to enter clinical studies as a potential treatment for multiple myeloma. The company was created to commercialise research led by Professor Guido Franzoso from the Department of Medicine at Imperial Col...

Moving Mountains for Multiple Myeloma

Moving Mountains for Multiple Myeloma is supported by the MMRF, CURE Media Group and Takeda. In addition to the Mt. Fuji 2017 climb, Moving Mountains for Multiple Myeloma treks planned for 2018 include a trip to Everest Base Camp in March. Funds raised by the Moving Mountains for Multiple Myeloma endeavors will go directly to research, supporting the MMRF ...

The Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to ...

GNS Healthcare and The Multiple Myeloma Research Foundation

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy’s diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatme...

GNS Healthcare (GNS) and Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy’s diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatme...

Relevant

Myeloma Canada

Multiple myeloma, a cancer of the bone marrow, is an incurable but treatable disease. The cancer starts in plasma cells, which are produced in the bone marrow. In myeloma, abnormal plasma cells, called myeloma cells, grow uncontrollably, crowding out the normal blood cells in the bone. This can bring on symptoms such as fatigue, recurrent infections and se...

Fortis Therapeutics, Inc.

Fortis Therapeutics is an immuno-oncology biotech developing a novel antibody-drug conjugate for late-stage multiple myeloma and metastatic castration-resistant prostate cancer. Fortis Therapeutics was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D. The company’s investors are Avalon Venture...

The Multiple Myeloma Research Consortium

The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 16 member institutions: University of California, San Francisco, City of Hope, Dana-Farber Cancer Institute, Emory...

Multiple Myeloma Research Consortium

The Multiple Myeloma Research Consortium (MMRC) is a 509(a) 3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 13 member institutions: University of California, San Francisco, City of Hope, Dana-Farber Cancer Institute, Emor...

Transition Therapeutics Inc

Transition Therapeutics Inc. is a fully integrated biopharmaceutical company with a proprietary state-of-the art drug discovery engine and extensive drug development program exploring novel therapeutics in multiple disease indications. The focus of the corporate business is to discover and advance lead molecules to the most valuable and competitive targets in the industry using our state-of-the-ar...

Tensha Therapeutics

Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders. The company’s programs are based on the discovery from the laboratory of Dr. James Bradner at Dana-Farber Cancer Institute of first-in-class, potent small molecule BET bromodomain ...

Cellerant Therapeutics Inc.

Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant’s lead product, CLT-008 is currently in Phase 1 clinical trials evaluating safety in pa...

The International Myeloma Foundation

Leading myeloma experts will discuss the latest treatment paradigms, coming out of ASH that could deliver the long-term survivors of the future, in a panel discussion moderated by Dr. Durie.

DeuteRx LLC

DeuteRx is pioneering ‘deuterium-enabled chiral switching’ (DECS), a revolutionary approach to improve racemic (a mixture of two mirror-image compounds or enantiomers) small molecule marketed drugs and drug candidates intended for patients across multiple therapeutic indications. Numerous drugs are still developed and marketed as racemic mixtures...

Transition Therapeutics Inc.

Transition Therapeutics Inc. is a fully integrated biopharmaceutical company with a proprietary state-of-the art drug discovery engine and extensive drug development program exploring novel therapeutics in multiple disease indications. The focus of the corporate business is to discover and advance lead molecules to the most valuable and competitive targets in the industry using our state-of-the-ar...

G1 Therapeutics, Inc.

G1 Therapeutics, Inc. is a privately held pharmaceutical company based in Chapel Hill, NC, that focuses on the discovery and development of novel small molecules for use in cancer therapy and biodefense applications. These molecules are being developed for targeting specific proteins associated with cell proliferation and growth. Such therapies may be usef...

Bruker Daltonics Inc

Since 1980, the Bruker Daltonics Corporation has developed as part of the global Bruker organization. Roots were the German Bruker-Franzen Analytik GmbH and the Swiss Spectrospin AG. These companies developed mobile detectors, as well as mass spectrometers for physical chemistry.From 1990 on, the Daltonics business received a new momentum: Technological innovation now allowed for the analysis of f...

Novus Therapeutics, Inc.

Novus Therapeutics is a specialty pharmaceutical company focused on developing products for disorders of the ear, nose, and throat (ENT). Novus has two technologies, each that has the potential to be developed for multiple ENT indications. The company’s lead product (OP-02) is a surfactant-based, combination drug product being developed as a potential...

Progen Pharmaceuticals

Progen Pharmaceuticals Limited (NASDAQ:PGLA; ASX: PGL) is a globally focused biotechnology company committed to improving patient outcomes through discovery and development of small molecule-based cancer therapeutics. The company has an intimate understanding of the role of heparan sulfate, a complex sugar, in cancer disease processes and have developed a small-molecule drug development program i...

Sinclair Pharma Limited

Sinclair Pharma is an international company operating in the fast growth, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive tre...

Enzo Biochem, Inc.

Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including exotic tests, to the medical community. Since our founding in 1976, our strategic focus has been on the development...


More From BioPortfolio on "Multiple Myeloma Therapeutics Major Developed Markets 2021 Growth"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks